Monday, June 27, 2016

Profound Medical, Royal Philips sell TULSA-PRO in Germany

Profound Medical, Royal Philips sell TULSA-PRO in Germany

June 21, 2016 by · Leave a Comment 

Tweet Profound Medical (TSX-V:PRN) and Royal Philips have jointly sold a TULSA-PRO system to University Hospital of Cologne, the first sale in Germany, following CE Mark approval in April 2016. TULSA-PRO is an innovative, minimally-invasive technique used to treat clinically organ-confined prostate cancer. The unique technology combines real-time MRI with transurethral robotically-driven ultrasound and closed-loop […]

Profound Medical, Royal Philips sell TULSA-PRO in UK

Profound Medical, Royal Philips sell TULSA-PRO in UK

June 20, 2016 by · Leave a Comment 

Tweet Profound Medical (TSX-V:PRN) and Royal Philips have jointly sold a TULSA-PRO system in the UK to University College London (UCL) and University College London Hospitals NHS Foundation Trust (UCLH). This marks the first sale under the company’s recent collaboration with Philips, following Profound’s receipt of CE Mark approval in April 2016. TULSA-PRO is a […]

ESSA Pharma takes unique approach to prostate cancer

ESSA Pharma takes unique approach to prostate cancer

June 7, 2016 by · Leave a Comment 

Tweet A marine sponge, Geodia lindgreni, native to Papua New Guinea may hold the key to a new approach in the treatment of prostrate cancer by ESSA Pharma (NASDAQ:EPIX; TSX:EPI). “Our scientific founders from the BC Cancer Agency and the University of British Columbia spent more than a decade conducting the basic biology research, identifying […]

FDA grants Profound Medical IDE approval for TULSA-PRO

FDA grants Profound Medical IDE approval for TULSA-PRO

May 19, 2016 by · Leave a Comment 

Tweet Profound Medical (TSX-V:PRN) has received investigational device exemption (IDE) approval from the FDA for a multicenter pivotal clinical trial to evaluate the efficacy of the TULSA-PRO System in patients with localized prostate cancer. TULSA-PRO, which has received CE Mark in Europe, combines real-time MRI with transurethral robotically-driven ultrasound and closed-loop thermal feedback control, providing […]

Profound Medical, Royal Phillips in TULSA-PRO sales pact

Profound Medical, Royal Phillips in TULSA-PRO sales pact

May 11, 2016 by · Leave a Comment 

http://www.youtube.com/watch?v=Wyy5jLOi8ac’]

Tweet Profound Medical (TSX-V:PRN) and Royal Philips have signed a sales and marketing agreement that will advance the commercial launch of Profound’s TULSA-PRO, a minimally invasive system to ablate targeted prostate tissue. Under the accord, the two companies will collaborate in the commercialization of TULSA-PRO in Europe followed by Canada, the U.S. and other markets, […]

Profound Medical readies pivotal clinical trial of TULSA-PRO

Profound Medical readies pivotal clinical trial of TULSA-PRO

May 3, 2016 by · Leave a Comment 

http://www.youtube.com/watch?v=Wyy5jLOi8ac’]

Tweet After receiving CE Mark approval last month of its minimally invasive transurethral ultrasound technology for the ablation of benign and malignant prostate tissue, known as TULSA-PRO, Profound Medical (TSX-V:PRN) plans to enroll 14 sites in the U.S., Canada and Europe in a pivotal trial for U.S. regulatory approval. “We have discussions ongoing with the […]

Profound Medical sells first TULSA-PRO device

Profound Medical sells first TULSA-PRO device

April 28, 2016 by · Leave a Comment 

Tweet Profound Medical (TSX-V:PRN) has made the first sale of its TULSA-PRO device to ResoFus Alomar in Barcelona, Spain. Profound’s novel technology combines real-time magnetic resonance imaging with transurethral robotically driven ultrasound and closed-loop thermal feedback control, providing a highly precise treatment tailored to patient-specific anatomy and pathology. TULSA-PRO has demonstrated accurate and precise ablation […]

Transition Therapeutics begins Phase 2 SARM study

Transition Therapeutics begins Phase 2 SARM study

April 26, 2016 by · Leave a Comment 

Tweet Transition Therapeutics (NASDAQ:TTHI, TSX:TTH) has dosed the first patient in a Phase 2 study of selective androgen receptor modulator (SARM) drug candidate, TT701. The Phase 2 study will evaluate the efficacy and safety of TT701 in improving the symptoms of androgen deficiency, including sexual symptoms, fatigue/low vitality, and physical dysfunction in men who have […]

GMP starts Profound Medical at speculative buy

GMP starts Profound Medical at speculative buy

April 12, 2016 by · Leave a Comment 

Tweet GMP Securities has initiated coverage of Profound Medical (TSX-V:PRN) with a “speculative buy” rating and price target of $2. The stock closed at $1.50 on Monday. The company is focused on developing and commercializing an innovative therapy for the ablation of prostate cancer tissue, using real-time MRI to greatly improve accuracy, while reducing side […]

Soricimed to present four posters at AACR

Soricimed to present four posters at AACR

April 12, 2016 by · Leave a Comment 

Tweet Closely-held Soricimed Biopharma and collaborators plan to present four posters at the American Association of Cancer Research (AACR) annual meeting in New Orleans on April 16-20. The presentations are based on preclinical and clinical research conducted on the company’s lead anti-cancer drug candidate, SOR-C13, a first-in-class inhibitor of the TRPV6 calcium channel. In February, […]

Next Page »

Email Newsletters with Constant Contact
Google+